All In Biotech

Drug Trial Radar · NCT06525298

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor, Trastuzumab Deruxtecan (T-DXd), or Darolutamide in Patients With Specified Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Sep 9, 2024

Primary completion

Sep 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Eisbach Bio GmbHIndustry
Sponsor type
Industry
Collaborators
M.D. Anderson Cancer Center
First posted
Jul 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).

Conditions

  • Advanced Solid Tumor
  • Homologous Recombination Deficiency
  • HRR Deficiency

Interventions

  • EIS-12656Drug

    EIS-12656 tablets given daily

  • PARPiDrug

    as per USPI/SmPC

  • Trastuzumab deruxtecanDrug

    as per USPI/SmPC

  • Darolutamide (BAY 1841788)Drug

    as per USPI/SmPC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and percentage of participants experiencing treatment-emergent adverse events (TEAEs)Time frame: From screening until end of treatment follow-up (45 days after last dose) (up to 7 months)
  2. Number and percentage of participants experiencing a dose limiting toxicity (DLT) (dose escalation part only)Time frame: Within 21 days of first dose

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • LSU Health Sciences Center- Shreveport

    Shreveport, Louisiana · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.